{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:59:01Z","timestamp":1706839141040},"reference-count":50,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,4,3]]},"DOI":"10.1080\/13696998.2016.1261032","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T14:19:35Z","timestamp":1479133175000},"page":"328-336","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data"],"prefix":"10.1080","volume":"20","author":[{"given":"Nanxin","family":"Li","sequence":"first","affiliation":[{"name":"Analysis Group, Boston, MA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangyi","family":"Fan","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todor","family":"Totev","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group, Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrata","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Joseph","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"CIT0001","unstructured":"NIH National Cancer Institute. Surveillance, epidemiology, and end results program (SEER) stat fact sheets: Chronic Myeloid Leukemia (CML). 2015, http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed October 27, 2015"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1126\/science.132.3438.1488"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402816"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","volume":"88","author":"Melo JV.","year":"1996","journal-title":"Blood"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1031107"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"CIT0008","unstructured":"Radich JP, Deininger M, Abboud CN, et\u00a0al. NCCN clinical practice guidelines in oncology: Chronic myelogenous leukemia, Version 1; 2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf. Accessed March 15, 2016"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3310\/hta16220"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3310\/hta16230"},{"key":"CIT0012","unstructured":"Whalen J, Ozer-Stillman I, Ambavane A, et\u00a0al. Cost-effectiveness analysis (CEA) of sequential treatment with tyrosine kinase inhibitors (TKIs) for chronic myelogenous leukemia (CML) (Poster). 56th ASH Annual Meeting and Exposition; December 6\u20139, 2014; San Francisco, CA. https:\/\/ash.confex.com\/ash\/2014\/webprogram\/Paper74905.html. Accessed July 14, 2016"},{"key":"CIT0013","unstructured":"Bristol-Myers Squibb Pharmaceuticals Ltd. Dasatinib (Sprycel) for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Multiple Technology Appraisal Submission to the National Institute for Health & Clinical Excellence; 2009"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.789012"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Minacori R, Bonastre J, Lueza B, et\u00a0al. How to model survival in cost-effectiveness analysis? Differences between Markov and partitioned survival analysis models. ISPOR 18th Annual European Congress; November 11, 2015; Milan, Italy. http:\/\/www.ispor.org\/research_pdfs\/51\/pdffiles\/PRM123.pdf. Accessed March 1, 2016","DOI":"10.1016\/j.jval.2015.09.2639"},{"key":"CIT0018","unstructured":"Pan F. Evaluation of treatment pathways in oncology: Modeling approaches. ISPOR; May 18\u201322, 2013; New Orleans, LA. http:\/\/www.ispor.org\/meetings\/neworleans0513\/releasedpresentations\/W27-Pan.pdf. Accessed March 14, 2014"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813040-00003"},{"key":"CIT0020","unstructured":"Federal Drug Administration (FDA). Highlights of prescribing information. SPRYCEL (dasatinib) tablet for oral use. FDA; August 2015, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021986s004lbl.pdf"},{"key":"CIT0021","unstructured":"Federal Drug Administration (FDA). Highlights of prescribing information. TASIGNA (nilotinib) capsules for oral use. FDA; January 2015, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022068lbl.pdf"},{"key":"CIT0022","volume-title":"Statistical analysis and control of dynamic systems","author":"Akaike H","year":"1988"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-71887-3"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1214\/14-EJS881"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344136"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1214\/08-AOAS207"},{"key":"CIT0027","first-page":"1","volume":"63","author":"Arias E.","year":"2014","journal-title":"Natl Vital Stat Rep"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00573.x"},{"key":"CIT0029","unstructured":"United States Bureau of Labor Statistics. Consumer Price Index (CPI); United States Bureau of Labor Statistics; 2014, http:\/\/www.bls.gov\/cpi\/"},{"key":"CIT0030","unstructured":"Truven Health Analytics MicroMedex Solutions. Red Book Online Search. 2015. http:\/\/www.redbook.com\/redbook. Accessed June 6, 2015"},{"key":"CIT0031","volume-title":"American Society of Hematology (ASH)","author":"Li N","year":"2015"},{"key":"CIT0032","unstructured":"Federal Drug Administration (FDA). Highlights of prescribing information. BOSULIF (bosutinib) tablet for oral use. November 2014, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf"},{"key":"CIT0033","unstructured":"Federal Drug Administration (FDA). Highlights of prescribing information. ICLUSIG (ponatinib) tablets for oral use. September 2014, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf"},{"key":"CIT0034","unstructured":"Federal Drug Administration (FDA). Highlights of prescribing information. SYNRIBO (omacetaxine mepesuccinate) for injection, for subcutaneous use. April 2014, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203585lbl.pdf"},{"key":"CIT0035","volume-title":"American Society of Hematology (ASH)","author":"Maziarz RT","year":"2015"},{"key":"CIT0036","unstructured":"CMS Physician Fee Schedule [Internet]. Centers for Medicare & Medicaid Services (CMS). 2015. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/overview.aspx. Accessed June 5, 2015"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.812034"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20694"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn103"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727060-00002"},{"key":"CIT0042","unstructured":"Healthcare Cost and Utilization Project\u2019s (HCUP) HCUPnet [Internet]. Agency for Healthcare Research and Quality, Rockville, MD; 2012. http:\/\/hcupnet.ahrq.gov\/. Accessed July 10, 2015"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.07.006"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.008"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/982395"},{"key":"CIT0046","first-page":"108","author":"Padula WV","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"CIT0047","unstructured":"National Health Expenditures 2014 Highlights. Centers for Medicare & Medicaid Services (CMS); 2015. https:\/\/www.cms.gov\/research-statistics-data-and-systems\/statistics-trends-and-reports\/nationalhealthexpenddata\/downloads\/highlights.pdf. Accessed February 5, 2016"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25150"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133109004885"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2016.1261032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:56:55Z","timestamp":1599436615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2016.1261032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4,3]]}},"alternative-id":["10.1080\/13696998.2016.1261032"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2016.1261032","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}